Pharma Hemp ®
L A B O R A T O R I E S

CERTIFICATE OF ANALYSIS No.: 2025-17428

CLIENT

Hemp Health Kft., Bartok Bela utca 16
9443 Petohaza, Hungary

SAMPLE *

Meliora CBD oil for dogs 6%

Sample condition:	SUITABLE	Work order:	2025-113069	Sample received:	17/11/2025
Sample ID:	2547031	Analysis ID:	2025_350	Start of analysis:	18/11/2025
Sample type:	Viscous liquid	Method ID:	PHL_RPC_16C	End of analysis:	19/11/2025
Batch No.: *	2025/088	Method SOP:	MET-LAB-001-08	Analyst:	Valentina Malin

* Information provided by the client.

CANNABINOID PROFILE		Concentration [% w/w]	Expanded uncertainty [% w/w]	Graphic presentation of relative cannabinoid concentration
CBDV	- Cannabidivarin	0.0318	0.0073	
CBDA	- Cannabidiolic acid	< LOQ	n/a	
CBGA	- Cannabigerolic acid	< LOQ	n/a	
CBG	- Cannabigerol	0.49	0.12	
CBD	- Cannabidiol	6.25	0.31	
THCV	- Tetrahydrocannabivarin	< LOQ	n/a	
CBN	- Cannabinol	0.0345	0.0076	
Δ^9-THC	- Δ-9-Tetrahydrocannabinol	< LOQ	n/a	
Δ^8-THC	- Δ-8-Tetrahydrocannabinol	< LOQ	n/a	
CBL	- Cannabicyclol	< LOQ	n/a	
CBC	- Cannabichromene	< LOQ	n/a	
Δ^9-THCA	- Δ-9-Tetrahydrocannabinolic acid	< LOQ	n/a	
CBV	- Cannabivarin	< LOQ	n/a	
CBCA	- Cannabichromenic acid	< LOQ	n/a	
CBT	- Cannabicitran	0.082	0.018	
CBE	- Cannabielsoin	0.058	0.016	

Units and abbreviations: **% w/w** = weight percent, **< LOQ** = below the limit of quantitation (0.03 % w/w), **ND** = not detected, **n/a** = not available.

The results given herein apply only to the sample as received and tested. **Expanded Uncertainty** was calculated using coverage factor k = 2, corresponding to a double standard uncertainty and characterizes the interval value in which it is possible to expect the real value with a probability of 95%. This is stated according to the ISO/IEC Guide 98-3.

Total or partial reproduction of this document is not allowed without the permit from PharmaHemp d.o.o. The document does not substitute any other legal document.

Date issued:

19/11/2025

Approved by:

_____
mag. Valentina Malin
Analytical Laboratory Manager

Authorized by:

_____
dr. Boštjan Jančar
Chief Technology Officer

End of Certificate